# Study of FYU-981 in Hyperuricemia With or Without Gout

> **NCT02344862** · PHASE2 · COMPLETED · sponsor: **Fuji Yakuhin Co., Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** FYU-981 High dose, (Oral daily dosing for 8 weeks)
- **DRUG:** FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
- **DRUG:** FYU-981 Low dose, (Oral daily dosing for 8 weeks)
- **DRUG:** Placebo, (Oral daily dosing for 8 weeks)

## Key facts

- **NCT ID:** NCT02344862
- **Lead sponsor:** Fuji Yakuhin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344862, "Study of FYU-981 in Hyperuricemia With or Without Gout". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02344862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*